Monitor Celcuity's commercial launch execution for REVTORPYK and upcoming clinical data readouts (VIKTORIA-2, CELC-G-201). The board appointment signals governance preparation for commercial-stage operations but is not a near-term catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Oct 2 $72.10entry
- T+1 · 4w ago +2.11%α +1.43% · $73.62
- T+5 · 27d ago −5.77%α −6.93% · $67.94
- T+20 · 6d ago −4.12%α −2.31% · $69.13
- T+23 · todayOpen
- T+60 · in 8w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity appointed David W. Gryska, a seasoned life sciences CFO (Incyte, Celgene), to its Board of Directors, effective October 1, 2026. The appointment, announced alongside the commercial launch of its first FDA-approved product REVTORPYK, adds independent financial and strategic expertise to the board as the company transitions to a commercial-stage biotech. This is a routine board expansion with no material financial impact.
Key Facts
- David W. Gryska appointed to Celcuity's Board of Directors on October 1, 2026.
- Board size increased from 8 to 9 members.
- Gryska will serve on the Audit Committee and Compensation Committee.
- Gryska receives pro-rated director compensation: $70,000 annual cash retainer and $100,000 annual equity award.
- Initial grant of 893 restricted stock units vesting by the earlier of the 2027 Annual Meeting or April 30, 2027.
- Appointment follows Celcuity's first FDA approval for REVTORPYK (gedatolisib) in HR+/HER2- advanced breast cancer.
Financial Impact
No material financial impact. Director compensation is standard: $70,000 annual cash retainer and $100,000 annual equity award.
Risk Factors
- Commercial launch execution risk for REVTORPYK in a competitive breast cancer landscape.
- Dependence on continued clinical trial success for gedatolisib in additional indications.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-411297 |
| Document: celc-ex99_1.htm | 0001193125-26-411297 |
| Document: 0001193125-26-411297-index-headers.html | 0001193125-26-411297 |
| Document: 0001193125-26-411297-index.html | 0001193125-26-411297 |
| Document: 0001193125-26-411297.txt | 0001193125-26-411297 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 2, 2026 2d ago | Institutional Cluster | $69.72 | awaiting T+5 | awaiting T+5 | $69.24 (−0.69%) |
Oct 24, 2026 11d ago | Press Release | $65.80 $69.13 | ▲ +5.06% | ▲ +6.32% | $69.24 (+5.23%) |
Oct 5, 2026 4w ago | 3 | $71.25 $63.19 | ▼ −11.31% | ▼ −11.17% | $69.24 (−2.82%) |
Oct 2, 2026 4w ago | 8-K | $72.10 $67.94 | ▼ −5.77% | ▼ −6.93% | $69.24 (−3.97%) |
Sep 30, 2026 5w ago | 8-K | $79.52 $65.78 | ▼ −17.28% | ▼ −19.19% | $69.24 (−12.93%) |
Sep 22, 2026 6w ago | Institutional Cluster | $84.10 $77.38 | ▼ −7.99% | ▼ −6.80% | $69.24 (−17.67%) |
Aug 26, 2026 10w ago | 8-K | $95.08 $96.20 | ▲ +1.18% | ▲ +1.30% | $69.24 (−27.18%) |
Jul 14, 2026 16w ago | 144 | $91.51 $90.14 | ▲ +1.50% | ▲ +0.52% | $69.24 (+24.34%) |
Jul 14, 2026 16w ago | Press Release | $91.51 $90.14 | ▼ −1.50% | ▼ −0.52% | $69.24 (−24.34%) |
Jun 11, 2026 20w ago | Institutional Cluster | $89.49 $88.05 | ▼ −1.61% | ▼ −2.04% | $69.24 (−22.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers